BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 31444102)

  • 1. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
    Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
    Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
    J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China.
    Fan X; Xiao M; Chen S; Kong F; Dou HT; Wang H; Xiao YL; Kang M; Sun ZY; Hu ZD; Wan Z; Chen SL; Liao K; Chu YZ; Hu TS; Zou GL; Hou X; Zhang L; Zhao YP; Xu YC; Liu ZY
    Clin Microbiol Infect; 2016 Oct; 22(10):887.e1-887.e9. PubMed ID: 27432767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
    Lee GA; Arthur I; Merritt A; Leung M
    Med Mycol; 2019 Nov; 57(8):1004-1010. PubMed ID: 30649538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
    Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
    Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
    Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
    Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
    Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates.
    Arsic Arsenijevic V; Pekmezovic MG; Meis JF; Hagen F
    Mycoses; 2014 Jun; 57(6):380-7. PubMed ID: 24438323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
    Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
    Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypic diversity and antifungal susceptibility of Cryptococcus neoformans isolates from paediatric patients in China.
    Hong N; Chen M; Xu N; Al-Hatmi AMS; Zhang C; Pan WH; Hagen F; Boekhout T; Xu J; Zou XB; Liao WQ
    Mycoses; 2019 Feb; 62(2):171-180. PubMed ID: 30341799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular typing of clinical Cryptococcus neoformans isolates collected in Germany from 2004 to 2010.
    Sanchini A; Smith IM; Sedlacek L; Schwarz R; Tintelnot K; Rickerts V
    Med Microbiol Immunol; 2014 Oct; 203(5):333-40. PubMed ID: 24838744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
    Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
    Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
    Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
    Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
    Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.
    Matos CS; de Souza Andrade A; Oliveira NS; Barros TF
    Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1647-52. PubMed ID: 22278291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients.
    Bertout S; Drakulovski P; Kouanfack C; Krasteva D; Ngouana T; Dunyach-Rémy C; Dongtsa J; Aghokeng A; Delaporte E; Koulla-Shiro S; Reynes J; Mallié M
    Clin Microbiol Infect; 2013 Aug; 19(8):763-9. PubMed ID: 23033854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
    Liaw SJ; Wu HC; Hsueh PR
    Clin Microbiol Infect; 2010 Jun; 16(6):696-703. PubMed ID: 19694765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular epidemiology and antifungal susceptibility profiles of clinical
    Bandalizadeh Z; Shokohi T; Badali H; Abastabar M; Babamahmoudi F; Davoodi L; Mardani M; Javanian M; Cheraghmakani H; Sepidgar AA; Badiee P; Khodavaisy S; Afshari SAK; Ahmadikia K; Seyedmousavi S
    J Med Microbiol; 2020 Jan; 69(1):72-81. PubMed ID: 31750814
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.